Combinatorial approach with mass spectrometry and lectin microarray dissected glycoproteomic features of virion-derived spike protein of SARS-CoV-2
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
The COVID-19 pandemic caused by the novel coronavirus, SARS-CoV-2, has a global impact on public health. Since glycosylation of the viral envelope glycoproteins is known to be deeply associated with their immunogenicity, intensive studies on the glycans of its major glycoprotein, S protein, have been conducted. Nevertheless, the detailed site-specific glycan compositions of virion-associated S protein have not yet been clarified. Here, we conducted intensive glycoproteomic analyses of SARS-CoV-2 S protein using a combinatorial approach with two different technologies: mass spectrometry (MS) and lectin microarray. Using our unique MS1-based glycoproteomic technique, Glyco-RIDGE, in addition to MS2-based Byonic search, we identified 1,759 site-specific glycan compositions. The most frequent was HexNAc:Hex:Fuc:NeuAc:NeuGc = 6:6:1:0:0, suggesting a tri-antennary N -glycan terminating with LacNAc and having bisecting GlcNAc and a core fucose, which was found in 20 of 22 glycosylated sites. The subsequent lectin microarray analysis emphasized intensive outer arm fucosylation of glycans, which efficiently complemented the glycoproteomic features. The present results illustrate the high-resolution glycoproteomic features of SARS-CoV-2 S protein and significantly contribute to vaccine design, as well as the understanding of viral protein synthesis.
Article activity feed
-
SciScore for 10.1101/2021.04.10.439300: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Antibodies: Rabbit monoclonal anti-SARS-CoV-2 spike S1 antibody, 007 (Cat# 40150-R007), and mouse monoclonal anti-SARS-CoV-2 spike neutralizing antibody, 43 (Cat# 40591-V05H1), were purchased from Sino Biological (Beijing, China). Antibodies: Rabbit monoclonal anti-SARS-CoV-2 spike S1 antibodysuggested: Noneanti-SARS-CoV-2 spike S1suggested: Noneanti-SARS-CoV-2 spike neutralizing antibody , 43suggested: NoneThese antibodies were biotinylated using the … SciScore for 10.1101/2021.04.10.439300: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Antibodies: Rabbit monoclonal anti-SARS-CoV-2 spike S1 antibody, 007 (Cat# 40150-R007), and mouse monoclonal anti-SARS-CoV-2 spike neutralizing antibody, 43 (Cat# 40591-V05H1), were purchased from Sino Biological (Beijing, China). Antibodies: Rabbit monoclonal anti-SARS-CoV-2 spike S1 antibodysuggested: Noneanti-SARS-CoV-2 spike S1suggested: Noneanti-SARS-CoV-2 spike neutralizing antibody , 43suggested: NoneThese antibodies were biotinylated using the Biotin Labeling Kit-NH2 (Dojindo, Kumamoto, Japan) Biotin Labeling Kit-NH2 ( Dojindo , Kumamoto , Japan)suggested: NoneExperimental Models: Cell Lines Sentences Resources VeroE6/TMPRSS2 cells were established in our laboratory as described previously23. VeroE6/TMPRSS2suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-